The Federal Joint Committee (G - BA) specified two appropriate comparator therapies according to the approval status: Treatment - naive patients, i.e. patients who had not been treated for HIV before, were to receive efavirenz in combination with tenofovir and emtricitabine or in combination
with abacavir and lamivudine.
Not exact matches
Detailed 48 - week results from a Phase 3 study evaluating the efficacy and safety of switching from a regimen containing
abacavir, dolutegravir and lamivudine (600 / 50/300 mg)(ABC / DTG / 3TC) to Biktarvy, a once - daily single tablet regimen, in virologically suppressed adults
with HIV.
Individuals
with the HLA - B * 5701 allele were found to be more likely to have a hypersensitivity reaction to
abacavir.
One example is
abacavir, a drug used in conjunction
with other antiretrovirals in the treatment of HIV infection.